{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:20:57Z","timestamp":1784996457845,"version":"3.55.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s40266-019-00696-3","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T02:04:00Z","timestamp":1563156240000},"page":"885-895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Management of Secondary Hyperparathyroidism in Chronic Kidney Disease: A Focus on the Elderly"],"prefix":"10.1007","volume":"36","author":[{"given":"Andrea","family":"Galassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Fasulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Carugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cianciolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-6252","authenticated-orcid":false,"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"696_CR1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification for renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945\u201353.","journal-title":"Kidney Int."},{"issue":"1","key":"696_CR2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ajkd.2005.09.024","volume":"47","author":"MD Danese","year":"2006","unstructured":"Danese MD, Kim J, Doan QV, et al. PTH and the risk for hip, vertebral and pelvic fractures among patients on dialysis. Am J Kidnei Dis. 2006;47(1):149\u201356.","journal-title":"Am J Kidnei Dis."},{"issue":"7","key":"696_CR3","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1093\/ndt\/gfs418","volume":"28","author":"JL Fernandez-Mart\u00ecn","year":"2013","unstructured":"Fernandez-Mart\u00ecn JL, Carrero JJ, Benedik M, et al. COSMOS: the dialysis scenario of CKD\u2013MBD in Europe. Nephrol Dial Transplant. 2013;28(7):1922\u201335.","journal-title":"Nephrol Dial Transplant."},{"key":"696_CR4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","volume":"10","author":"F Tentori","year":"2015","unstructured":"Tentori F, Wang M, Bieber BA, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10:98\u2013109.","journal-title":"Clin J Am Soc Nephrol."},{"key":"696_CR5","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","volume":"26","author":"D Fouque","year":"2011","unstructured":"Fouque D, Roth H, Pelletier S, et al. Control of mineral metabolism and bone disease in haemodialsysis patients: which optimal targets? Nephrol Dial Transplant. 2011;26:1948\u201355.","journal-title":"Nephrol Dial Transplant."},{"key":"696_CR6","first-page":"S1","volume":"Suppl 13","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2013MBD Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2013MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD\u2013MBD). Kidney Int Suppl. 2009;Suppl 13:S1\u2013130.","journal-title":"Kidney Int Suppl"},{"issue":"Suppl 1","key":"696_CR7","first-page":"1","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2013MBD Uptodate Work Group","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2013MBD Uptodate Work Group. KDIGO 2017. Clinical practice guideline update for the diagnosis, evaluation, prevention and treatment of CKD\u2013MBD. Kidney Int Suppl (2011). 2017;7(Suppl 1):1\u201359.","journal-title":"Kidney Int Suppl (2011)."},{"issue":"1","key":"696_CR8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hdi.12315","volume":"20","author":"R Fissell","year":"2016","unstructured":"Fissell R, Karaboyas A, Bieber BA, et al. Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS. Hemodial Int. 2016;20(1):38\u201349.","journal-title":"Hemodial Int."},{"key":"696_CR9","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","volume":"4","author":"YW Chiu","year":"2009","unstructured":"Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4:1089\u201396.","journal-title":"Clin J Am Soc Nephrol."},{"key":"696_CR10","volume-title":"2015 USRDS annual data report: Epidemiology of kidney disease in the United States","author":"United States Renal Data System","year":"2015","unstructured":"United States Renal Data System. 2015 USRDS annual data report: Epidemiology of kidney disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2015."},{"key":"696_CR11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/jama.294.6.716","volume":"294","author":"CM Boyd","year":"2005","unstructured":"Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid disease. JAMA. 2005;294:716\u201324.","journal-title":"JAMA."},{"issue":"27","key":"696_CR12","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1056\/NEJMsb042458","volume":"351","author":"ME Tinetti","year":"2004","unstructured":"Tinetti ME, Bogardus S, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004;351(27):2870\u20134.","journal-title":"N Engl J Med."},{"issue":"6","key":"696_CR13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamainternmed.2017.0911","volume":"177","author":"C Carroll","year":"2017","unstructured":"Carroll C, Hassain A. Polypharmacy in the elderly-when good drugs lead to bad outcomes. JAMA Intern Med. 2017;177(6):871.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"696_CR14","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/ki.2015.245","volume":"88","author":"CG Couchoud","year":"2015","unstructured":"Couchoud CG, Beuscart JB, Aldigier JC, et al. Development of a risk stratification algorithm to improve patient-centered care and decision making for incident elderly patients with end-stage renal disease. Kidney Int. 2015;88(5):1178\u201386.","journal-title":"Kidney Int."},{"issue":"4","key":"696_CR15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s40620-014-0142-4","volume":"28","author":"A Galassi","year":"2014","unstructured":"Galassi A, Cupisti A, Santoro A, et al. Phosphate handling in ESRD: diet, dialysis and binders against the low evident masked pool. J Nephrol. 2014;28(4):415\u201329.","journal-title":"J Nephrol."},{"issue":"4","key":"696_CR16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1525-139X.2007.00309.x","volume":"20","author":"J Uribarri","year":"2007","unstructured":"Uribarri J. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin Dial. 2007;20(4):295\u2013301.","journal-title":"Semin Dial."},{"key":"696_CR17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.nutr.25.050304.092642","volume":"25","author":"HS Tenenhouse","year":"2005","unstructured":"Tenenhouse HS. Regulation of phosphate homeostasis by the type IIaNa\/phosphate cotransporter. Ann Rev Nutr. 2005;25:197\u2013214.","journal-title":"Ann Rev Nutr."},{"key":"696_CR18","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/sj.ki.5002163","volume":"71","author":"PU Torres","year":"2007","unstructured":"Torres PU, Prie\u2019 D, Molina Bletry V, et al. Klotho: an antiaging protein involved in mineral and vitamin D metabolism. Kidney Int. 2007;71:730\u20137.","journal-title":"Kidney Int."},{"issue":"2","key":"696_CR19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/1570161115666170310092202","volume":"16","author":"G Cianciolo","year":"2018","unstructured":"Cianciolo G, Galassi A, Capelli I, et al. Klotho-FGF23, cardiovascular disease, and vascular calcification: black or white? Curr Vac Pharmacol. 2018;16(2):143\u201356.","journal-title":"Curr Vac Pharmacol."},{"key":"696_CR20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00041552-199607000-00006","volume":"5","author":"M Rodriguez","year":"1996","unstructured":"Rodriguez M, Almaden Y, Hernandez A, Torres A. Effect of phosphate on the parathyroid gland: direct and indirect? Curr Opin Nephrol Hypertens. 1996;5:321\u20138.","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"696_CR21","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1172\/JCI114043","volume":"83","author":"AA Portale","year":"1989","unstructured":"Portale AA, Halloran BP, Morris RC Jr. Physiologic regulation of the serum concentration of 1,25-dihydroxy vitamin D by phosphorus in normal men. J Clin Investig. 1989;83:1494\u20139.","journal-title":"J Clin Investig"},{"key":"696_CR22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.kint.2015.12.004","volume":"89","author":"TB Drueke","year":"2016","unstructured":"Drueke TB, Massy ZA. Changing bone patterns with progression of chronic kidney disease. Kidney Int. 2016;89:289\u2013302.","journal-title":"Kidney Int."},{"key":"696_CR23","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/ndt\/gfv099","volume":"30","author":"JL Fernandez-Mart\u00ecn","year":"2015","unstructured":"Fernandez-Mart\u00ecn JL, Martinez-Camblor P, Dionisi MP, et al. Improvement of mineral and bone metabolis markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant. 2015;30:1542\u201351.","journal-title":"Nephrol Dial Transplant."},{"key":"696_CR24","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/sj.ki.5000311","volume":"69","author":"FC Barreto","year":"2006","unstructured":"Barreto FC, Barreto DV, Moyses RMA, et al. Osteoporosis in hemodialysis patientes revisited by bone histomorphometry: a new insight into an old problem. Kidney Int. 2006;69:1852\u20137.","journal-title":"Kidney Int."},{"issue":"4","key":"696_CR25","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","volume":"67","author":"SM Sprague","year":"2016","unstructured":"Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis. 2016;67(4):559\u201366.","journal-title":"Am J Kidney Dis."},{"key":"696_CR26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ki.2008.60","volume":"73","author":"DL Andress","year":"2008","unstructured":"Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int. 2008;73:1345\u201354.","journal-title":"Kidney Int."},{"issue":"2","key":"696_CR27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.bone.2013.07.037","volume":"57","author":"Y Iwasaki","year":"2013","unstructured":"Iwasaki Y, Kazama JJ, Yamato H, et al. Accumulated ureic toxins attenuate bone mechanical properties in rats with chronic kidney disease. Bone. 2013;57(2):477\u201383.","journal-title":"Bone."},{"key":"696_CR28","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/toxins4111309","volume":"4","author":"Y Akiyama","year":"2012","unstructured":"Akiyama Y, Yakeuchi Y, Kikuchi K, et al. A metabolomic approach to clarifying the effect of AST-120 on 5\/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS). Toxins (Basel). 2012;4:1309\u201322.","journal-title":"Toxins (Basel)."},{"key":"696_CR29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bone.2013.07.002","volume":"56","author":"H Tanaka","year":"2013","unstructured":"Tanaka H, Iwasaki Y, Yamato H, et al. P-Cresyl sulfate induces osteobast dysfunction through activating JNK and p38 MPAK pathways. Bone. 2013;56:347\u201354.","journal-title":"Bone."},{"key":"696_CR30","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/kisup.2013.93","volume":"3","author":"JJ Kazama","year":"2013","unstructured":"Kazama JJ, Iwasaki Y, Fukagawa M. Uremic osteoporosis. Kidney Int. 2013;3:446\u201350.","journal-title":"Kidney Int."},{"key":"696_CR31","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1093\/ndt\/gfq128","volume":"25","author":"S Pelletier","year":"2010","unstructured":"Pelletier S, Roth H, Bouchet JL, et al. Mineral and bone disease pattern in elderly haemodialysis patients. Nephrol Dial transplant. 2010;25:3062\u201370.","journal-title":"Nephrol Dial transplant."},{"key":"696_CR32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jbmr.5650100121","volume":"10","author":"Y Pei","year":"1995","unstructured":"Pei Y, Hercz G, Greenwood C, et al. Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res. 1995;10:149\u201356.","journal-title":"J Bone Miner Res."},{"key":"696_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/1471-2369-14-15","volume":"14","author":"I Kiss","year":"2013","unstructured":"Kiss I, Kiss Z, Ambrus C, et al. Age-dependent parathormone levels and different CKD\u2013MBD treatment practices of dialysis patients in Hungary\u2014results from a nationwide clinical audit. BMC Nephrol. 2013;14:155. \n                    https:\/\/doi.org\/10.1186\/1471-2369-14-15\n                    \n                  .","journal-title":"BMC Nephrol."},{"issue":"5","key":"696_CR34","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/j.1523-1755.2000.00394.x","volume":"58","author":"CO Stehman-Breen","year":"2000","unstructured":"Stehman-Breen CO, Sherrard DJ, Alem AM, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58(5):2200\u20135.","journal-title":"Kidney Int."},{"key":"696_CR35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/ndt\/gft352","volume":"29","author":"J Wagner","year":"2014","unstructured":"Wagner J, Jhaveri KD, Rosen L, et al. Increased bone fractures among elderly United States hemodialysis patients. Nephrol Dial Transplant. 2014;29:146\u201351.","journal-title":"Nephrol Dial Transplant."},{"key":"696_CR36","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/ageing\/afq044","volume":"39","author":"JA Stevens","year":"2010","unstructured":"Stevens JA, Anne RuddR. Declining hip fracture rates in the United States. Age Ageing. 2010;39:500\u20133.","journal-title":"Age Ageing."},{"key":"696_CR37","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/jbmr.1684","volume":"27","author":"NC Wright","year":"2012","unstructured":"Wright NC, Saag KG, Curtis JR, et al. Recent trends in hip fracture rates by race\/ethnicity among older US adults. J Bone Miner Res. 2012;27:2325\u201332.","journal-title":"J Bone Miner Res."},{"key":"696_CR38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ki.2013.279","volume":"85","author":"F Tentori","year":"2013","unstructured":"Tentori F, McCullough K, Kilpatrick RD, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int. 2013;85:166\u201373.","journal-title":"Kidney Int."},{"key":"696_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12882-016-0234-6","volume":"17","author":"O Swift","year":"2016","unstructured":"Swift O, Ayub A, Mathavakkannan S, et al. Outcomes following surgery for fractured neck of femur in dialysis patients: a 5-year review from a district general hospital in the United Kingdom. BMC Nephrol. 2016;17:26. \n                    https:\/\/doi.org\/10.1186\/s12882-016-0234-6\n                    \n                  .","journal-title":"BMC Nephrol."},{"issue":"6","key":"696_CR40","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00402-018-2898-9","volume":"138","author":"V Puvanesarajah","year":"2018","unstructured":"Puvanesarajah V, Amin R, Qureshi R, et al. Outcomes following surgical management of femoral neck fractures in elderly dialysis-dependent patients. Arch Orthop Trauma Surg. 2018;138(6):757\u201364.","journal-title":"Arch Orthop Trauma Surg."},{"key":"696_CR41","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","volume":"68","author":"J Cunningham","year":"2005","unstructured":"Cunningham J, Danese M, Oloson K. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793\u2013800.","journal-title":"Kidney Int."},{"key":"696_CR42","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","volume":"26","author":"S Moe","year":"2015","unstructured":"Moe S, Abdala S, Chertow GM, et al. Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J Am Soc Nephrol. 2015;26:1466\u201375.","journal-title":"J Am Soc Nephrol."},{"key":"696_CR43","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/MNH.0000000000000326","volume":"26","author":"H Komaba","year":"2017","unstructured":"Komaba H, Nakamura M, Fukagawa M. Resurgence of parathyroidectomy: evidence and outcomes. Curr Opin Nephrol Hypertens. 2017;26:243\u20139.","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"696_CR44","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1681\/ASN.2007010022","volume":"18","author":"KD Rudser","year":"2007","unstructured":"Rudser KD, de Boer IH, Dooley A, et al. Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol. 2007;18:2401\u20137.","journal-title":"J Am Soc Nephrol."},{"key":"696_CR45","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1007\/s00268-017-4000-0","volume":"41","author":"E Isaksson","year":"2017","unstructured":"Isaksson E, Ivarsson K, Akaberi S, et al. The effect of parathyroidectomy on risk of hip fracture in secondary hyperparathyroidism. World J Sur. 2017;41:2304\u201311.","journal-title":"World J Sur."},{"key":"696_CR46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2004030203","volume":"16","author":"RN Foley","year":"2005","unstructured":"Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk of cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489\u201395.","journal-title":"J Am Soc Nephrol."},{"issue":"9900","key":"696_CR47","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","volume":"382","author":"SA Jamal","year":"2013","unstructured":"Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268\u201377.","journal-title":"Lancet."},{"issue":"2","key":"696_CR48","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2215\/CJN.06800615","volume":"11","author":"L Patel","year":"2016","unstructured":"Patel L, Bernard LM, Elder GJ, et al. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol CJASN. 2016;11(2):232\u201344.","journal-title":"Clin J Am Soc Nephrol CJASN."},{"key":"696_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","author":"M Ruospo","year":"2018","unstructured":"Ruospo M, Palmer SC, Natale P, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD\u2013MBD). Cochrane Database Syst Rev. 2018. \n                    https:\/\/doi.org\/10.1002\/14651858\n                    \n                  .","journal-title":"Cochrane Database Syst Rev."},{"key":"696_CR50","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","volume":"72","author":"WN Suki","year":"2007","unstructured":"Suki WN, Zbaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130\u20137.","journal-title":"Kidney Int."},{"key":"696_CR51","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1185\/03007990903399398","volume":"25","author":"R Wilson","year":"2009","unstructured":"Wilson R, Zhang P, Smyth M, et al. Assessment survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Opin. 2009;25:3021\u20138.","journal-title":"Curr Med Opin."},{"key":"696_CR52","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/ki.2013.185","volume":"84","author":"JB Cannata-And\u00eca","year":"2013","unstructured":"Cannata-And\u00eca JB, Fernandez-mart\u00ecin JL, Locatelli F, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int. 2013;84:998\u20131008.","journal-title":"Kidney Int."},{"issue":"8","key":"696_CR53","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3109\/0886022X.2014.938544","volume":"36","author":"L Liu","year":"2014","unstructured":"Liu L, Wang Y, Chen H, et al. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials. Renal Fail. 2014;36(8):1244\u201352.","journal-title":"Renal Fail."},{"issue":"2","key":"696_CR54","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/ndt\/gfq691","volume":"26","author":"M Cozzolino","year":"2011","unstructured":"Cozzolino M, Mazzaferro S, Brandenburg V. The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders? Nephrol Dial Transplant. 2011;26(2):402\u20137.","journal-title":"Nephrol Dial Transplant."},{"key":"696_CR55","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/864012","author":"A Galassi","year":"2013","unstructured":"Galassi A, Bellasi A, Auricchio S, et al. Which vitamin D in CKD\u2013MBD? The time of burning questions. Biomed Res Int. 2013. \n                    https:\/\/doi.org\/10.1155\/2013\/864012\n                    \n                  .","journal-title":"Biomed Res Int."},{"issue":"9","key":"696_CR56","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/ndt\/gfs108","volume":"27","author":"M Cozzolino","year":"2012","unstructured":"Cozzolino M, Brancaccio D, Cannella G, et al. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH\u2009\u2264\u2009150\u00a0pg\/ml : results of the Italian FARO survey. Nephrol Dial Transplant. 2012;27(9):3588\u201394.","journal-title":"Nephrol Dial Transplant."},{"issue":"7","key":"696_CR57","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","volume":"307","author":"R Thadhani","year":"2012","unstructured":"Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674\u201384.","journal-title":"JAMA."},{"issue":"1","key":"696_CR58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2013010103","volume":"25","author":"AY Wang","year":"2014","unstructured":"Wang AY, Fang F, Chan J, et al. Effect of paricalcitol on left ventricular mass and function in CKD\u2014the OPERA trial. J Am Soc Nephrol. 2014;25(1):175\u201386.","journal-title":"J Am Soc Nephrol."},{"issue":"22","key":"696_CR59","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1001\/jama.2018.17749","volume":"320","author":"T Shoji","year":"2018","unstructured":"Shoji T, Inaba M, Fukagawa M, et al. Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism receiving hemodialysis. The J-DAVID randomized trial. JAMA. 2018;320(22):2325\u201334.","journal-title":"JAMA."},{"issue":"4","key":"696_CR60","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial transplant. 2011;26(4):1327\u201339.","journal-title":"Nephrol Dial transplant."},{"key":"696_CR61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","volume":"132","author":"SM Moe","year":"2015","unstructured":"Moe SM, Chertow GM, Parfrey PS, et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015;132:27\u201339.","journal-title":"Circulation."},{"key":"696_CR62","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2215\/CJN.07730814","volume":"10","author":"PS Parfrey","year":"2015","unstructured":"Parfrey PS, Drueke TB, Block GA, et al. The effect of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet Hcl therapy to loower cardiovascular events (EVOLVE) trial. Clin J Am Soc Nephrol. 2015;10:791\u20139.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"696_CR63","doi-asserted-by":"crossref","first-page":"800","DOI":"10.2215\/CJN.10221014","volume":"10","author":"J Floege","year":"2015","unstructured":"Floege J, Kubo Y, Floege A. The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: the EVOLVE trial. Clin J am soc Nephrol. 2015;10(5):800\u20137.","journal-title":"Clin J am soc Nephrol."},{"issue":"8","key":"696_CR64","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/0272989X16638312","volume":"36","author":"AH Briggs","year":"2016","unstructured":"Briggs AH, Parfrey PS, Khan N, et al. Analyzing health-related quality of life in the EVOLVE trial: the joint impact of treatment and clinical events. Med Decis making. 2016;36(8):965\u201372.","journal-title":"Med Decis making."},{"key":"696_CR65","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/ki.2015.72","volume":"88","author":"H Komaba","year":"2015","unstructured":"Komaba H, Taniguchi M, Wada A, et al. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2015;88:350\u20139.","journal-title":"Kidney Int"},{"issue":"11","key":"696_CR66","doi-asserted-by":"crossref","first-page":"e0187025","DOI":"10.1371\/journal.pone.0187025","volume":"12","author":"M Apetril","year":"2017","unstructured":"Apetril M, Goldsmith D, Nistor I, et al. Impact of surgical parathyroidectomy on chronic kidney disease-mineral bone disorder (CKD\u2013MBD)\u2014a systematic review and meta-analysis. PLoS One. 2017;12(11):e0187025.","journal-title":"PLoS One."},{"key":"696_CR67","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/ndt\/gfv334","volume":"30","author":"KM Ivarsson","year":"2015","unstructured":"Ivarsson KM, Akaberi S, Isaksson E, et al. The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism. Nephrol Dial Transplant. 2015;30:2027\u201333.","journal-title":"Nephrol Dial Transplant."},{"key":"696_CR68","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.03520414","volume":"10","author":"A Ishani","year":"2015","unstructured":"Ishani A, Liu J, Wetmore JB, et al. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol. 2015;10:90\u20137.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"696_CR69","doi-asserted-by":"crossref","first-page":"e22696","DOI":"10.1002\/jcla.22696","volume":"33","author":"J Wan","year":"2019","unstructured":"Wan J, Li W, Zhong Y. Parathyroidectomy decreases serum intact parathyroid hormone and calcium levels and prolongs overall survival in elderly hemodialysis patients with severe secondary hyperparathyroidism. J Clin Lab Anal. 2019;33(3):e22696.","journal-title":"J Clin Lab Anal."},{"key":"696_CR70","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMp1113631","volume":"366","author":"DB Reuben","year":"2012","unstructured":"Reuben DB, Tinetti ME. Goal-oriented patient care\u2014an alternative health outcomes paradigm. N Engl J Med. 2012;366:777\u20139.","journal-title":"N Engl J Med."},{"key":"696_CR71","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12882-017-0665-8","volume":"18","author":"B Hauber","year":"2017","unstructured":"Hauber B, Caloyeras J, Posner J, et al. Hemodialysis patients\u2019 preferences for the management of secondary hyperparathyroidism. BMC Nephrol. 2017;18:254. \n                    https:\/\/doi.org\/10.1186\/s12882-017-0665-8\n                    \n                  .","journal-title":"BMC Nephrol."},{"key":"696_CR72","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/ki.2011.384","volume":"82","author":"MK Tamura","year":"2012","unstructured":"Tamura MK, Tan JC, O\u2019Hare AM. Optimizing renal replacement therapy in older adults: a framework for making individualized decision. Kidney Int. 2012;82:261\u20139.","journal-title":"Kidney Int."},{"key":"696_CR73","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0272-6386(05)80027-7","volume":"37","author":"AH Moss","year":"2001","unstructured":"Moss AH. Shared decision making in dialysis: the new RPA\/ASN guideline on appropriate initiation and withdrawal of treatment. Am J Kidney Dis. 2001;37:1081\u201391.","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"696_CR74","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1525-139X.2011.00849.x","volume":"24","author":"JT Daugirdas","year":"2011","unstructured":"Daugirdas JT, Finn WF, Emmett M, et al. Frequent hemodialysis network trial group. The phosphate binder equivalent dose. Semin Dial. 2011;24(1):41\u20139.","journal-title":"Semin Dial."},{"key":"696_CR75","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1093\/ndt\/gfn310","volume":"23","author":"A Hutchinson","year":"2008","unstructured":"Hutchinson A, Laville M. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant. 2008;23:3677\u201384.","journal-title":"Nephrol Dial Transplant."},{"key":"696_CR76","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s108490","author":"M Cozzolino","year":"2017","unstructured":"Cozzolino M, Galassi A, Conte F, et al. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide. Ther Clin Risk Manag. 2017. \n                    https:\/\/doi.org\/10.2147\/tcrm.s108490\n                    \n                  .","journal-title":"Ther Clin Risk Manag."},{"issue":"2","key":"696_CR77","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Blushinsky DA, Cunningham J, et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA. 2017;317(2):146\u201355.","journal-title":"JAMA."},{"issue":"2","key":"696_CR78","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Blushinsky DA, Cheng S, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317(2):156\u201364.","journal-title":"JAMA."},{"issue":"1","key":"696_CR79","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12882-016-0342-3","volume":"17","author":"A Cupisti","year":"2016","unstructured":"Cupisti A, D\u2019Alessandro C, Di Iorio B, et al. Nutritional support in the tertiary care of patients affected by chronic renal insufficiency: report of a step-wise, personalized, pragmatic approach. BMC Nephrol. 2016;17(1):124. \n                    https:\/\/doi.org\/10.1186\/s12882-016-0342-3\n                    \n                  .","journal-title":"BMC Nephrol"},{"issue":"6","key":"696_CR80","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s10157-018-1591-1","volume":"22","author":"L Milanova","year":"2018","unstructured":"Milanova L, Fomin V, Moiseev S, et al. Effect of essential amino acid ketoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Klotho) in 3b-4 stages chronic kidney disease patients: a randomized pilot study. Clin Exp Nephrol. 2018;22(6):1351\u20139.","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"696_CR81","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2215\/CJN.05040610","volume":"6","author":"SM Moe","year":"2011","unstructured":"Moe SM, Zidehsarai MP, Chambers MA, et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(2):257\u201364.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"696_CR82","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/17512433.2017.1371011","volume":"10","author":"A Galassi","year":"2017","unstructured":"Galassi A, Bellasi A, Ciceri P, et al. Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease. Expert Rev Clin Pharmacol. 2017;10(10):1073\u201384.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"696_CR83","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/ndt\/gfn026","volume":"23","author":"GA Block","year":"2008","unstructured":"Block GA, Zeig S, Sugihara J, et al. Combined therapy with cinacalcet and low dose of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2008;23(7):2311\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"696_CR84","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/ndt\/gfr668","volume":"27","author":"D Hansen","year":"2012","unstructured":"Hansen D, Rasmussen K, Pedersen SM, Rasmussen LM, Brandi L. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant. 2012;27(6):2263\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"696_CR85","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","volume":"27","author":"M Ketteler","year":"2012","unstructured":"Ketteler M, Martin KJ, Wolf M, et al. Paricalcitol versus cinacalcet plus low dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant. 2012;27(8):3270\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"696_CR86","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2174\/15701611113119990021","volume":"12","author":"M Rodrigues","year":"2014","unstructured":"Rodrigues M, Munoz-Castaneda JR, Almaden Y. Therapeutic use of calcitriol. Curr Vasc Pharmacol. 2014;12(2):294\u20139.","journal-title":"Curr Vasc Pharmacol"},{"issue":"4","key":"696_CR87","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ndt\/gfu011","volume":"29","author":"M Cozzolino","year":"2014","unstructured":"Cozzolino M, Ketteler M, Martin KJ, et al. Paricalcitol or cinacalcet centred therapy affects marker of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT. Nephrol Dial Transplant. 2014;29(4):899\u2013905.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"696_CR88","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/15701611113119990024","volume":"12","author":"S Mazzaferro","year":"2014","unstructured":"Mazzaferro S, Goldsmith D, Larsson TE, et al. Vitamin D metabolites and\/or analogs: which D for which patient? Curr Vasc Pharmacol. 2014;12(2):339\u201349.","journal-title":"Curr Vasc Pharmacol"},{"issue":"9","key":"696_CR89","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.10661013","volume":"9","author":"DW Coyne","year":"2014","unstructured":"Coyne DW, Goldberg S, Faber M, et al. A randomized multi center trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3\u20134 CKD. Clin J Am Soc Nephrol. 2014;9(9):1620\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"696_CR90","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2215\/CJN.07050714","volume":"10","author":"JB Wetmore","year":"2015","unstructured":"Wetmore JB, Gurevich K, Sprague S, et al. A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015;10(6):1031\u201340.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"26","key":"696_CR91","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"GM Chertow","year":"2012","unstructured":"Chertow GM, Block GA, Correa-Rotter CA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482\u201394.","journal-title":"N Engl J Med"},{"issue":"6","key":"696_CR92","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10157-019-01692-y","volume":"23","author":"K Tsuruya","year":"2019","unstructured":"Tsuruya K, Shimazaki R, Fukagawa M, et al. Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients. Clin Exp Nephrol. 2019;23(6):739\u201348.","journal-title":"Clin Exp Nephrol"},{"issue":"11","key":"696_CR93","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1093\/ndt\/gfl395","volume":"21","author":"A Galassi","year":"2006","unstructured":"Galassi A, Spiegel DM, Bellasi A, et al. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialsysis diabetic patients receving calcium binders. Nephrol Dial Transplant. 2006;21(11):3215\u201322.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"696_CR94","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1093\/ndt\/gfr144","volume":"26","author":"E Gonzalez-Parra","year":"2011","unstructured":"Gonzalez-Parra E, Gonzalez-Causuas ML, G\u00e0lan A, et al. Lanthanum carbonate reduces FGF-23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant. 2011;26(8):2567\u201371.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"696_CR95","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/s10157-016-1362-9","volume":"21","author":"YM Chang","year":"2017","unstructured":"Chang YM, Tsai SC, Shiao CC, et al. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 qnd hepcidin levels in chronic hemodialysis patients. Clin Exp Nephrol. 2017;21(5):908\u201316.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"696_CR96","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s13104-018-3483-6","volume":"11","author":"H Shima","year":"2018","unstructured":"Shima H, Miya K, Okada K, et al. Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improbe renal anemia in hemodialysis patients. BMC Res Notes. 2018;11(1):363. \n                    https:\/\/doi.org\/10.1186\/s13104-018-3483-6\n                    \n                  .","journal-title":"BMC Res Notes"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00696-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-019-00696-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00696-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T23:12:41Z","timestamp":1594681961000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-019-00696-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":96,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["696"],"URL":"https:\/\/doi.org\/10.1007\/s40266-019-00696-3","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,15]]},"assertion":[{"value":"15 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All authors (AG, PC, EF, SC, GC and MC) declare no conflicts of interest for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No funding to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}